Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:06 PM
Ignite Modification Date:
2025-12-24 @ 1:06 PM
NCT ID:
NCT01353261
Eligibility Criteria:
Inclusion Criteria:
* Patient \>18 years old.
* Patient scheduled to undergo PCI for either stable CAD or AMI:
* Stable CAD defined as negative cardiac isoenzymes prior to the PCI as well as no resting ECG changes indicative of ACS.
* AMI defined as positive cardiac isoenzymes prior to the PCI and/or resting ECG changes indicative of ACS.
3\. Patients treated with a loading dose of clopidogrel at least 6 hours prior to the blood draw or on a maintenance dose of clopidogrel (of at least 75mg QD) for a minimum of 5 days.
Exclusion Criteria:
* Known allergies to aspirin, clopidogrel, or prasugrel
* Use of a glycoprotein (GP) IIb/IIIa inhibitor within 8 hours of the blood draw;
* Patient known to be pregnant or lactating;
* Patient with known history of bleeding diathesis or currently active bleeding;
* Platelet count \<100,000/mm the day of the blood draw;
* Hematocrit \<25% the day of the blood draw;
* On warfarin therapy at the time of the blood draw or the need for warfarin therapy in the subsequent month following the blood draw;
* Known blood transfusion within the preceding 10 days of the blood draw;
* Patient who has received NSAID (not including ASA) within preceding 24 hours of the blood draw;
* Patients presenting with cardiogenic shock;
* Any significant medical condition, which in the investigator's opinion may interfere with the patient's optimal participation in the study.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01353261
Study Brief:
Protocol Section:
NCT01353261